secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001193125-23-034390
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics cuts 55% of workforce, appoints interim CEO as Lucchino takes medical leave
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $83.1M as of Dec 31, 2022 (preliminary); $68.9M net of debt.
- Workforce reduction of ~55% approved Feb 11, 2023; completion by April 30, 2023; ~$4M in severance costs.
- CEO David Lucchino on temporary medical leave due to bacterial meningitis; co-founder/CSO Christopher Loose named Interim CEO.
- Chief Development Officer Carl LeBel stepping down effective March 31, 2023 as part of the reduction.
- Company focusing capital on pre-clinical remyelination program for Multiple Sclerosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/0001193125-23-034390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523034390/d463460d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-034390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer